Latest ASX Announcements

Non-Renounceable Entitlement Offer to Raise Approximately $5,524,906

Highlights 

  • One (1) for two (2) pro-rata non-renounceable entitlement offer at $0.12 per share to raise approximately $5,524,906.
  • Commitments received from major shareholders, directors and management for at least $800,000.
  • Funds raised will be used to further the development plans for DMX-200 for both FSGS and diabetic nephropathy and for pre-clinical pipeline programs. For DMX-200 […]
By | 2017-12-06T07:10:32+00:00 December 6th, 2017|Latest ASX Announcements|

ASX: Dimerix presenting further DMX-200 Phase 2a data at World Diabetes Conference

Dimerix Limited announces that the chair of the Medical Advisory Board, Associate Professor Dr David Packham has been invited to present both an oral and poster presentation of DMX-200 Phase 2a subgroup results at the 2nd World Congress for Clinical Trials in Diabetes between November 27-28 in Berlin, Germany.

The World Congress for Clinical Trials in […]

By | 2017-11-27T05:39:20+00:00 November 27th, 2017|Latest ASX Announcements|

Dimerix Phase 2a Subgroup Analysis Results

Dimerix Presents Detailed Subgroup Analysis from DMX-200 Phase 2a trial in Chronic Kidney Disease Showing Compelling Efficacy Signals in Diabetic Nephropathy Patients

  • Detailed data from Dimerix’s DMX-200 Phase 2a trial in Chronic Kidney Disease (CKD) presented at American Society of Nephrology’s (ASN) Annual Kidney Week conference in New Orleans this week
  • Post hoc, detailed data […]
By | 2017-11-02T06:46:11+00:00 November 2nd, 2017|Latest ASX Announcements|